Holen Sie sich die Stockscreener-App
6.30
11.52%
-0.82
Handel nachbörslich:
6.39
0.09
+1.43%
Schlusskurs vom Vortag:
$7.12
Offen:
$6.35
24-Stunden-Volumen:
4.21M
Relative Volume:
1.52
Marktkapitalisierung:
$496.37M
Einnahmen:
$214.30M
Nettoeinkommen (Verlust:
$162.50M
KGV:
3.0685
EPS:
2.0531
Netto-Cashflow:
$74.42M
1W Leistung:
-14.29%
1M Leistung:
-14.29%
6M Leistung:
-49.19%
1J Leistung:
-37.69%
1-Tages-Spanne:
$6.1301
$6.55
1-Wochen-Bereich:
$6.1301
$7.265
52-Wochen-Spanne:
$5.60
$17.43
CorMedix Inc Stock (CRMD) Company Profile
Firmenname
CorMedix Inc
Sektor
Branche
Telefon
908-517-9500
Adresse
400 Connell Drive, 5th Floor, Suite 5000, Berkeley Heights, NJ
Compare CRMD vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRMD
CorMedix Inc
|
6.30 | 560.98M | 214.30M | 162.50M | 74.42M | 2.0531 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
CorMedix Inc Stock (CRMD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-20 | Hochstufung | D. Boral Capital | Hold → Buy |
| 2025-06-30 | Herabstufung | D. Boral Capital | Buy → Hold |
| 2025-06-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-03-07 | Eingeleitet | Leerink Partners | Outperform |
| 2025-01-13 | Eingeleitet | D. Boral Capital | Buy |
| 2024-08-26 | Eingeleitet | Rodman & Renshaw | Buy |
| 2023-08-10 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-02-17 | Eingeleitet | Needham | Buy |
| 2020-09-29 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2020-09-21 | Eingeleitet | Truist | Buy |
| 2019-12-18 | Eingeleitet | B. Riley FBR | Buy |
| 2019-03-26 | Bestätigt | H.C. Wainwright | Buy |
| 2018-12-06 | Eingeleitet | ROTH Capital | Buy |
| 2017-09-25 | Bestätigt | H.C. Wainwright | Buy |
| 2017-08-10 | Bestätigt | Rodman & Renshaw | Buy |
| 2017-05-05 | Bestätigt | Rodman & Renshaw | Buy |
| 2016-11-11 | Bestätigt | FBR & Co. | Outperform |
| 2016-03-17 | Bestätigt | FBR Capital | Outperform |
| 2016-03-03 | Eingeleitet | FBR Capital | Outperform |
| 2015-11-16 | Bestätigt | ROTH Capital | Neutral |
| 2015-10-29 | Bestätigt | ROTH Capital | Neutral |
| 2015-05-06 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2014-12-08 | Bestätigt | ROTH Capital | Buy |
| 2011-10-03 | Herabstufung | Maxim Group | Buy → Hold |
Alle ansehen
CorMedix Inc Aktie (CRMD) Neueste Nachrichten
Truist reiterates CorMedix stock rating on steady guidance - Investing.com
Why Did CRMD Stock Tumble Over 11% Today? - Stocktwits
CorMedix Shares Fall After Q4 Profit Miss - marketscreener.com
CorMedix: Fourth Quarter Financial Results Overview - Bitget
CorMedix (CRMD) Q4 2025 Earnings Call Transcript - AOL.com
CorMedix stock falls after earnings miss (CRMD:NASDAQ) - Seeking Alpha
Earnings call transcript: CorMedix Q4 2025 results miss EPS, stock dips - Investing.com Nigeria
CorMedix (CRMD) Lags Q4 Earnings Estimates - Yahoo Finance
CorMedix Q4 2025 Earnings Call Transcript - MarketBeat
Cormedix Earnings Review: Q4 Summary - Benzinga
CorMedix earnings missed by $0.69, revenue topped estimates - Investing.com
CorMedix: Q4 Earnings Snapshot - KVUE
CorMedix reports Q4 revenue of $128.6M, reaffirms 2026 guidance - Investing.com
CORMEDIX ($CRMD) Releases Q4 2025 Earnings - Quiver Quantitative
CorMedix stock falls 5% on fourth quarter earnings miss - Investing.com India
CorMedix Inc. Reports Fourth Quarter and Full Year 2025 Financial Results - TradingView
CorMedix reports Q4 revenue of $128.6M, reaffirms 2026 guidance By Investing.com - Investing.com UK
CorMedix Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - The Manila Times
Cormedix Stock Pre-Market (+6.2%) : Technical Move Ahead of Key Q2 Catalyst - Trefis
Cormedix Earnings Preview - Benzinga
CRMD Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Earnings Preview: CorMedix to Report Financial Results Pre-market on March 05 - 富途牛牛
CorMedix Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 5, 2026 - marketscreener.com
CorMedix Inc. to Report Fourth Quarter and Full Year 2025 - GlobeNewswire
Responsive Playbooks and the CRMD Inflection - Stock Traders Daily
CRMD Earnings History & Surprises | EPS & Revenue Results | CORMEDIX INC (NASDAQ:CRMD) - ChartMill
Is It Time To Revisit CorMedix (CRMD) After Its Sharp Year To Date Decline? - Yahoo Finance
CRMD SEC FilingsCormedix 10-K, 10-Q, 8-K Forms - Stock Titan
CorMedix Expands With Melinta Buy As Valuation Gap Draws Attention - Sahm
CorMedix Inc. (CRMD): Investor Outlook With A Promising 102% Upside Potential - DirectorsTalk Interviews
Evaluating CorMedix (CRMD) Valuation As Melinta Acquisition And DefenCath Outlook Refocus Investor Attention - simplywall.st
CRMD vs. TBPH: Which Small-Cap Biotech Stock Is the Better Bet? - TradingView
Should Investors Buy, Sell or Hold CRMD Stock Ahead of Q4 Earnings? - Finviz
A Pivotal Spring Agenda for CorMedix Investors - AD HOC NEWS
CorMedix Inc. (CRMD) board approves multi-year $75M stock buyback - MSN
Understanding the Setup: (CRMD) and Scalable Risk - Stock Traders Daily
Buyback Watch: Why is CorMedix Inc stock going downMarket Growth Review & Daily Volume Surge Trade Alerts - baoquankhu1.vn
CorMedix Down 27% in 3 Months: Is It Time to Sell the Stock? - Bitget
Why CorMedix Inc. stock attracts high net worth investorsRate Cut & Free High Return Stock Watch Alerts - mfd.ru
What is CorMedix Inc.’s book value per shareJuly 2025 Highlights & Reliable Breakout Stock Forecasts - mfd.ru
CorMedix Inc. (CRMD) Investor Outlook: 101.86% Potential Upside Sparks Interest - DirectorsTalk Interviews
Can CorMedix's Melinta acquisition aid growth beyond DefenCath? - MSN
CorMedix Buyback And Melinta Integration Reframe Anti Infectives Growth Story - Yahoo Finance
Aug Wrap: What makes CorMedix Inc stock attractive todayMarket Sentiment Summary & Capital Protection Trade Alerts - baoquankhu1.vn
Finanzdaten der CorMedix Inc-Aktie (CRMD)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.69%
0.68%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):